Navigation Links
GSK Announces Changes to Corporate Executive Team
Date:4/30/2008

PHILADELPHIA and LONDON, April 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced a number of changes to its Corporate Executive management team. In a message to employees, Andrew Witty, CEO designate, detailed new appointments and his new management team which will take effect on May 22nd when he assumes the role of Chief Executive Officer.

Outlining the context for these changes, Andrew Witty said: "It is clear that our industry is facing a rapidly changing environment. Demand for innovative medicines and healthcare products continues to grow, however we are also presented with increasing challenges, such as cost containment, regulatory pressures and generic competition."

To address these challenges, Witty stated that the company must work hard to increase GSK's global reach and presence, and ensure that vaccines, consumer healthcare and pharmaceuticals all play their full potential. He emphasized the need for GSK's business regions to drive sales growth, and announced new operational structures to expand and improve GSK's capability, particularly in emerging markets and in Asia.

"Emerging markets, such as Brazil, Russia, India, China and the Middle East, are significant growth drivers of the future. They are already contributing close to 25% of today's market growth and are forecast to grow even faster in the future, around triple the rate of western countries. It is essential that we have an operating structure that is dynamic and responsive to the opportunities in these markets," said Witty.

"I am therefore creating a new Emerging Markets region which will ensure that we devote the focus required to build on our excellent foundations in those markets and truly establish ourselves as a trusted, long-term partner, one that is actively working to address the specific healthcare needs in those countries," he said.

A new Asia Pacific region will also be created, which includes Japan and Australia. Witty noted that many of these countries have sophisticated and well-organized healthcare systems and that these markets represent "significant and immediate opportunities" for existing products and products which will be launched over the next few years.

As part of the changes to business regions, GSK has also realigned markets in North America (combining the US, Canadian and Puerto Rican businesses) and has established new operational areas in Europe to maximize their potential and opportunities for growth.

Witty also placed emphasis on the development of GSK's business through partnership and collaboration, and announced a new dedicated team for Corporate Strategy and Development:

"Making the changes required to develop our business for the next decade requires a rigorous and disciplined focus on corporate strategy. A key element of this new team's remit will be to proactively seek new business opportunities to expand our global reach and drive sales growth," he said. Finally, Witty also spoke to measures to improve processes and ensure that the company works effectively and efficiently. He also placed great emphasis on the need to sustain and develop the strong ethical culture of GSK:

"Ultimately, our culture and our people will be the key factors in our success. We need to ensure that we always do what is right for the patients and I want GSK to meet the highest standards expected of us by society," said Witty.

GSK Corporate Executive Team (effective May 22nd 2008):

-- Andrew Witty, Chief Executive Officer*

-- Julian Heslop, Chief Financial Officer*

-- Moncef Slaoui, Chairman, Research & Development*

-- Chris Viehbacher, President, North American Pharmaceuticals*

-- Simon Bicknell, SVP, Company Secretary & Compliance Officer

-- John Clarke, President, Consumer Healthcare

-- Marc Dunoyer, President, Asia Pacific

-- Eddie Gray, President, Pharmaceuticals Europe

-- Abbas Hussain, President, Emerging Markets. Abbas will join GSK on 2

June from Eli Lilly and Company, where he has spent 20 years overseeing

markets throughout Europe, Africa/Middle East and Australasia

-- Duncan Learmouth, SVP, Corporate Communications & Global Community

Partnerships

-- Bill Louv, Chief Information Officer

-- Dan Phelan, Chief of Staff

-- David Pulman, President, Global Manufacturing & Supply

-- David Redfern, Chief Strategy Officer

-- Jean Stephenne, President and General Manager, Biologicals

-- Claire Thomas, SVP, Human Resources

-- SVP & General Counsel (currently vacant)

* Executive directors who are also members of GSK's Board of Directors

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at http://www.gsk.com.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Summit VetPharm Announces New Distributor Partnership with Webster Veterinary
2. Psychemedics Corporation Announces First Quarter Results
3. InfoLogix Announces First Quarter 2008 Financial Results
4. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
5. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
6. ATS Medical Announces First Frontiers in Cryoablation Symposium
7. Carriage Services Announces First Quarter Earnings Release and Conference Call Schedule
8. Warner Chilcott Announces Settlement of Securities Litigation
9. SXC Health Solutions announces completion of exchange offer for NMHC
10. Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes
11. WellPoint Announces Acquisition of DeCare Dental
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology: